Edition:
India

Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

1.77USD
25 Nov 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.77
Open
$1.59
Day's High
$1.82
Day's Low
$1.59
Volume
691,121
Avg. Vol
513,272
52-wk High
$4.38
52-wk Low
$1.14

Latest Key Developments (Source: Significant Developments)

Athersys Inc Files For Mixed Shelf Of Upto $100 Million
Friday, 17 Jan 2020 

Jan 16 (Reuters) - Athersys Inc ::ATHERSYS INC FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING.  Full Article

Athersys Q2 Loss Per Share $0.06
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Athersys Inc ::ATHERSYS REPORTS SECOND QUARTER 2019 RESULTS.Q2 LOSS PER SHARE $0.06.Q2 REVENUE $4.3 MILLION VERSUS $19.4 MILLION.  Full Article

Athersys Inc Enters Open Market Sale Agreement With Jefferies LLC To Offer And Sell Shares Up To $50.0 Million
Friday, 31 May 2019 

May 30 (Reuters) - Athersys Inc ::ATHERSYS INC - ENTERED INTO AN OPEN MARKET SALE AGREEMENT WITH JEFFERIES LLC TO OFFER AND SELL SHARES UP TO $50.0 MILLION - SEC FILING.  Full Article

Athersys Q4 Earnings Per Share Estimate $-0.08 -- Refinitiv Ibes Data
Friday, 15 Mar 2019 

March 14 (Reuters) - Athersys Inc ::ATHERSYS ANNOUNCES FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2018.Q4 LOSS PER SHARE $0.08.Q4 REVENUE $1.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $1.5 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.ENDED 2018 WITH $51.1 MILLION IN CASH AND CASH EQUIVALENTS.AT FEB 2019 END, CO HAD $51.5 MILLION IN CASH AND CASH EQUIVALENTS.  Full Article

Athersys Announces Results From Exploratory Clinical Study Of Multistem Cell Therapy For Acute Respiratory Distress Syndrome
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Athersys Inc ::ATHERSYS ANNOUNCES POSITIVE RESULTS FROM ITS EXPLORATORY CLINICAL STUDY OF MULTISTEM® CELL THERAPY FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS).ATHERSYS INC - WILL CONTINUE TO EVALUATE DATA AS ONE-YEAR FOLLOW-UP PERIOD IS COMPLETED FOR ALL PATIENTS IN TRIAL FOR MULTISTEM.ATHERSYS - ENDED YEAR WITH ABOUT $51 MILLION IN CASH AND CASH EQUIVALENTS.ATHERSYS INC - LOWER MORTALITY OF 25% IN MULTISTEM TREATMENT GROUP VERSUS. 40% IN PLACEBO GROUP FOR MULTISTEM.  Full Article

Healios To Make Payment To Extend Exclusive Period For Negotiating Option For License To Multistem Therapy For Indications In China
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Athersys Inc ::HEALIOS AGREES TO MAKE PAYMENT TO EXTEND EXCLUSIVE PERIOD FOR NEGOTIATING AN OPTION FOR A LICENSE TO MULTISTEM® THERAPY FOR INDICATIONS IN CHINA.ATHERSYS INC - HEALIOS HAS AGREED TO MAKE A ONE-TIME $2.0 MILLION PAYMENT IN DECEMBER 2018 FOR AN EXTENSION THROUGH JUNE 30, 2019.ATHERSYS INC - HEALIOS MAY MAKE ADDITIONAL PAYMENT OF $3.0 MILLION TO EXTEND NEGOTIATION PERIOD THROUGH DEC31, 2019.ATHERSYS - PAYMENTS BY HEALIOS WOULD BE CREDITABLE AGAINST $15 MILLION OPTION FEE THAT WOULD BE PAYABLE UPON EXECUTION OF CHINA OPTION AGREEMENT.  Full Article

BRIEF-Athersys Says May From Time To Time Issue Up To 35 Mln Shares Of Common Stock In One Or More Offerings

* ATHERSYS INC SAYS MAY FROM TIME TO TIME ISSUE UP TO 35 MILLION SHARES OF COMMON STOCK IN ONE OR MORE OFFERINGS - SEC FILING Source text: (https://bit.ly/36Hc7tO) Further company coverage: